• Nanion Technologies: Smart Tools for Ion Channel Research

    Nanion Technologies: Smart Tools for Ion Channel Research

  • SyncroPatch 384: HTS Automated Patch Clamp

    SyncroPatch 384: HTS Automated Patch Clamp

  • SURFE²R 96SE: Label-free HTS Transporter Screening

    SURFE²R 96SE: Label-free HTS Transporter Screening

  • Dynamic Clamp: Patchliner

    Dynamic Clamp: Patchliner

  • Bilayer recordings: Orbit product family

    Bilayer recordings: Orbit product family

  • CardioExcyte 96 SOL: Pacing Cardiomyocytes with Light

    CardioExcyte 96 SOL: Pacing Cardiomyocytes with Light

Our Product Portfolio

SyncroPatch 384

SyncroPatch 384

Patchliner

Patchliner

Port-a-Patch

Port-a-Patch

Port-a-Patch mini

Port-a-Patch mini

CardioExcyte 96

CardioExcyte 96

FLEXcyte 96

FLEXcyte 96

SURFE²R 96SE

SURFE²R 96SE

SURFE²R N1

SURFE²R N1

Orbit 16 TC

Orbit 16 TC

Orbit Mini

Orbit Mini

Vesicle Prep Pro

Vesicle Prep Pro

Buffer Solution

Buffer Solution

07.06.2016 | External Webinar: A new analysis capability to improve assessment of cardiac liability in high throughput electrophysiology

icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i)

AstraZeneca has implemented the Nanion SyncroPatch 384PE electrophysiology platform. This webinar will show how AstraZeneca and Genedata developed a processing and analysis pipeline for the complex data, reading binary raw data directly from the instrument into Genedata Screener.
Organisation: Genedata AG.

Speakers:

Ana Teixeira and Matthew Bridgelend-Taylor, AstraZeneca, Cambridge, UK

Description:

Automated patch clamp screens generate highly valuable information for drug research programs. Therefore, AstraZeneca has implemented the Nanion SyncroPatch 384PE electrophysiology platform, capturing full kinetics of channel response at higher throughput for hERG and other key cardiac ion channels. AstraZeneca and Genedata then developed a processing and analysis pipeline for this complex data, reading binary raw data directly from the instrument into Genedata Screener, then assigning and integrating the sweep recordings and finally subjecting them to scientists’ review. Additional methods to normalize the cumulative curve recordings and to automatically detect “slow onset” compounds were developed. This investment in a next-generation automated electrophysiology platform and an appropriate automated data processing pipeline is resulting in more predictive and affordable safety screens at high scalability and rapid turnover for discovery projects across AstraZeneca.


Playback

Back to Overview

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.